About TaiGen Biotechnology
TaiGen Biotechnology is a publicly listed company based in Taipei (Taiwan) founded in 2001. Therapeutics for infectious diseases and cancer are developed and commercialized. TaiGen Biotechnology has raised $99 million across 5 funding rounds from investors including Cathay Life Insurance, China Steel Corporation and CDIB Capital Group. Its chief executive, as recorded, is Ming-Chu Hsu. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Diversified.
Company details
TaiGen Biotechnology focuses on the discovery, development, and commercialization of therapeutics to treat cancers, infectious diseases and diabetic complications (limb ischemia and retinopathy). It markets Nemonoxacin, a drug-resistant anti-infection drug for community-acquired pneumonia. It is developing Burixafor (TG-0054) which is a potent and selective CXCR4 chemokine receptor antagonist. Burixafor rapidly mobilizes stem cells and progenitor cells from the bone marrow into peripheral circulation and has applications in Hematological cancer chemosensitization, Stem cell transplantation and Treatment in myocardial infarction. Also developing Furaprevir (TG-2349), a novel inhibitor of Hepatitis C virus (HCV) NS34A protease. The company has operations in Taiwan, China, and the U.S.
- Headquarters Taipei, Taiwan
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website taigenbiotech.com
- Social LinkedIn
- Legal Name Taigen Biopharmaceuticals Holdings Limited
- Annual Revenue$259.47 M72.24as on Dec 31, 2025
- Net Profit$45.18 Mas on Dec 31, 2025
- EBITDA$86.87 Mas on Dec 31, 2025
- Total Equity Funding$99M (USD)
in 5 rounds
- Latest Funding Round$37M (USD), Series C
Jan 2009
- InvestorsCathay Life Insurance
& 12 more
Funding Insights of TaiGen Biotechnology
TaiGen Biotechnology has successfully raised a total of $99M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $37 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $99M
- Total Rounds 5
- Last Round Series C — $37M
- First Round $24M
(Aug 2001)
- Investors Count 13
All 5 funding rounds of TaiGen Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2009 | $37M | Series C | – | – | |
| Nov 2005 | $3.5M | Grant | – | – | |
| Mar 2004 | $38M | Series B | – | – | |
| Oct 2003 | $890,000 | Grant | – | – | |
| Aug 2001 | $24M | Series A | – | – |
13 investors in total: 13 institutional.
Investors in TaiGen Biotechnology
TaiGen Biotechnology has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Cathay Life Insurance, China Steel Corporation and CDIB Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| df.gov.tw | ||||
Sector-agnostic investments are made in early-stage Asia Pacific startups. | 1959 | cdibcapitalgroup.com | Taipei, Taiwan | |
| hotung.com.tw | ||||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Pulp, paper, printing, and electronic components are manufactured. | 1924 | yfy.com | Taipei, Taiwan | |
Brand of sugar | 1946 | taisugar.com.tw | Tainan, Taiwan | |
| ey.gov.tw | ||||
Steel products including plates, bars, coils, and alloys are produced. | 1971 | csc.com.tw | Kaohsiung City, Taiwan | |
Life, health & travel insurance firm | 1963 | skl.com.tw | Taipei, Taiwan | |
Life insurance policies are issued and managed in Taiwan. | 1962 | cathaylife.com.tw | Taipei, Taiwan |
Investor details for TaiGen Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TaiGen Biotechnology
1 people are tracked at TaiGen Biotechnology (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ming-Chu Hsu | CEO | Leadership |
Complete people profiles for TaiGen Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of TaiGen Biotechnology
TaiGen Biotechnology is a publicly listed company on the TPEX with ticker symbol 4157 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Aug 2013
- Listed onTT: 4157
- Listed entityTaiGen Biopharmaceuticals Holdings Limited
- Exchange sectorHealth technology
- ISINKYG866171005
- Share price8.92 TWD (+0.56% on the day) · 2026-10-14
- Market capitalisation6,313,963,570.00 TWD
- Price to earnings41.3
- EPS (diluted, trailing year)0.22 TWD
- Volume (last session)920,471
Financials of TaiGen Biotechnology
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 259.5M TWD | 45.2M TWD | 86.9M TWD |
| 2024 | 150.7M TWD | -38.6M TWD | -97.3M TWD |
| 2023 | 123.1M TWD | 136.7M TWD | -147.1M TWD |
| 2022 | 36.2M TWD | -237.2M TWD | -249.1M TWD |
| 2021 | 1.29B TWD | 775.6M TWD | 928.3M TWD |
Detailed financial statements for TaiGen Biotechnology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of TaiGen Biotechnology
4 dated milestones of TaiGen Biotechnology across 12 years, from founding to its latest funding, stage changes and deals.
- Founded TaiGen Biotechnology is founded.
- Funding First funding round of $24.0M.
- Funding Latest funding round, Series C, of $37.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of TaiGen Biotechnology
The website of TaiGen Biotechnology (taigenbiotech.com) receives about 1.8K visits a month and ranks #8,037,594 among all websites worldwide, #7,233 in Biotechnology and Pharmaceuticals.
- Monthly visits1.8K
▼ 6.7% vs previous month
- Global rank#8,037,594
among all websites
- Category rank#7,233
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.9
- Average visit53 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with TaiGen Biotechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
phytopharm.com | phytopharm.com | 100% | – | ||
nanotherapeutics.com | nanotherapeutics.com | 100% | – | ||
| cytomyx.com | 100% | View details | |||
thrombogenics.com | thrombogenics.com | 100% | – | ||
| protemix.co.nz | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for TaiGen Biotechnology
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Taigen Biotechnology
Complete news archive for TaiGen Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TaiGen Biotechnology
TaiGen Biotechnology was founded in 2001.
TaiGen Biotechnology is headquartered in Taipei, Taiwan.
Ming-Chu Hsu is the CEO of TaiGen Biotechnology, as recorded in our data.
TaiGen Biotechnology is a funded company, having raised a total of $99M across 5 funding rounds to date. The company's 1st funding round was a Series A of $24M, raised on Aug 2001.
TaiGen Biotechnology focuses on the discovery, development, and commercialization of therapeutics to treat cancers, infectious diseases and diabetic complications (limb ischemia and retinopathy). It markets Nemonoxacin, a drug-resistant anti-infection drug for community-acquired pneumonia. It is developing Burixafor (TG-0054) which is a potent and selective CXCR4 chemokine receptor antagonist. Burixafor rapidly mobilizes stem cells and progenitor cells from the bone marrow into peripheral circulation and has applications in Hematological cancer chemosensitization, Stem cell transplantation and Treatment in myocardial infarction. Also developing Furaprevir (TG-2349), a novel inhibitor of Hepatitis C virus (HCV) NS34A protease. The company has operations in Taiwan, China, and the U.S.
Yes, TaiGen Biotechnology is publicly traded on TPEX under the ticker symbol 4157.
TaiGen Biotechnology has 13 investors. Key investors include Cathay Life Insurance, China Steel Corporation, CDIB Capital Group, YFY, and CSRC.